134 related articles for article (PubMed ID: 16009907)
1. High sensitivity measurement of CRP and disease progression in multiple sclerosis.
Soilu-Hänninen M; Koskinen JO; Laaksonen M; Hänninen A; Lilius EM; Waris M
Neurology; 2005 Jul; 65(1):153-5. PubMed ID: 16009907
[TBL] [Abstract][Full Text] [Related]
2. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
Freedman MS; Forrestal FG
Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
[TBL] [Abstract][Full Text] [Related]
3. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
5. Seeing injectable MS therapies differently: they are more similar than different.
Fox RJ; Arnold DL
Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
[No Abstract] [Full Text] [Related]
6. Interferon inhibitory activity in patients with multiple sclerosis.
Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Sellner J; Greeve I; Mattle HP
Mult Scler; 2008 Aug; 14(7):981-4. PubMed ID: 18573823
[TBL] [Abstract][Full Text] [Related]
8. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
10. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
11. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Annunziata P; Giorgio A; De Santi L; Zipoli V; Portaccio E; Amato MP; Clerici R; Scarpini E; Moscato G; Iudice A; Vacca G; Orefice G; Morra VB; Maimone D
J Neurol Sci; 2006 May; 244(1-2):97-102. PubMed ID: 16473370
[TBL] [Abstract][Full Text] [Related]
12. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
[TBL] [Abstract][Full Text] [Related]
13. HLA class II and response to interferon-beta in multiple sclerosis.
Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
[TBL] [Abstract][Full Text] [Related]
14. Increased CXCL8 (IL-8) expression in Multiple Sclerosis.
Lund BT; Ashikian N; Ta HQ; Chakryan Y; Manoukian K; Groshen S; Gilmore W; Cheema GS; Stohl W; Burnett ME; Ko D; Kachuck NJ; Weiner LP
J Neuroimmunol; 2004 Oct; 155(1-2):161-71. PubMed ID: 15342208
[TBL] [Abstract][Full Text] [Related]
15. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients.
Bartosik-Psujek H; Stelmasiak Z
Clin Neurol Neurosurg; 2006 Oct; 108(7):644-7. PubMed ID: 16343740
[TBL] [Abstract][Full Text] [Related]
16. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
17. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
Oger J; Francis G; Chang P;
J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
[TBL] [Abstract][Full Text] [Related]
18. Plasma S100beta and NSE levels and progression in multiple sclerosis.
Koch M; Mostert J; Heersema D; Teelken A; De Keyser J
J Neurol Sci; 2007 Jan; 252(2):154-8. PubMed ID: 17187827
[TBL] [Abstract][Full Text] [Related]
19. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
